Compare TREE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREE | DSGN |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 693.0M | 579.9M |
| IPO Year | N/A | 2021 |
| Metric | TREE | DSGN |
|---|---|---|
| Price | $38.52 | $10.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $75.00 | $15.00 |
| AVG Volume (30 Days) | ★ 405.9K | 288.8K |
| Earning Date | 03-02-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $1,059,158,000.00 | N/A |
| Revenue This Year | $22.86 | N/A |
| Revenue Next Year | $7.32 | N/A |
| P/E Ratio | $40.67 | ★ N/A |
| Revenue Growth | ★ 37.01 | N/A |
| 52 Week Low | $33.50 | $2.60 |
| 52 Week High | $77.35 | $10.97 |
| Indicator | TREE | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 27.97 | 51.02 |
| Support Level | $42.86 | $9.54 |
| Resistance Level | $48.98 | $10.59 |
| Average True Range (ATR) | 3.83 | 0.63 |
| MACD | -1.93 | -0.05 |
| Stochastic Oscillator | 2.36 | 35.47 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.